Reports Outline Prostate Cancer Study Results from Michigan Medicine [Durable Benefit From Poly(Adp-ribose) Polymerase Inhibitors In Metastatic Prostate Cancer In Routine Practice: Biomarker Associations and Implications for Optimal Clinical...].

A report from Michigan Medicine discusses the effectiveness of poly(ADP-ribose) polymerase inhibitors (PARPis) in patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in homologous recombination repair (HRR) genes. The study found that PARPis were more effective in patients with BRCA1 or BRCA2 alterations (BRCAalt) compared to alterations in other HRR genes. Within the BRCAalt group, patients with homozygous loss of BRCA had better outcomes. The study suggests that tissue testing should be prioritized over liquid biopsy to identify patients who may benefit most from PARPis. [Extracted from the article]